Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Sarit Assouline et al.|The Lancet Oncology|2022Cited by 429
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryJosé López‐Sendón, Teresa López‐Fernández, Carlos Álvarez-Ortega et al.|European Heart Journal|2020Cited by 282